Exelixis
EXEL
#2109
Rank
ยฃ5.74 B
Marketcap
ยฃ20.13
Share price
-1.53%
Change (1 day)
15.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of June 2024 : ยฃ1.61 B

According to Exelixis's latest financial reports the company has ยฃ1.61 B in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$ยฃ1.77 B-13.61%
2022-12-31$ยฃ2.05 B25.93%
2021-12-31$ยฃ1.63 B18.67%
2020-12-31$ยฃ1.37 B8.34%
2019-12-31$ยฃ1.27 B25.91%
2018-12-31$ยฃ1.00 B378.56%
2017-12-31$ยฃ0.21 B191.28%
2016-12-31$ยฃ72.38 M-176.26%
2015-12-31$-ยฃ94.92 M28.68%
2014-12-31$-ยฃ73.77 M-283.91%
2013-12-31$ยฃ40.1 M-78.12%
2012-12-31$ยฃ0.18 B214.38%
2011-12-31$ยฃ58.31 M-139.29%
2010-12-31$-ยฃ0.15 B45.5%
2009-12-31$-ยฃ0.11 B161.4%
2008-12-31$-ยฃ39.02 M-191.11%
2007-12-31$ยฃ42.82 M-7.42%
2006-12-31$ยฃ46.25 M39.23%
2005-12-31$ยฃ33.22 M25.77%
2004-12-31$ยฃ26.41 M-70.99%
2003-12-31$ยฃ91.05 M-17.01%
2002-12-31$ยฃ0.10 B-32.94%
2001-12-31$ยฃ0.16 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
ยฃ13.27 B 721.92%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ59.62 B 3,591.58%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ33.25 B 1,959.13%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ13.00 B 705.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ4.51 B 179.52%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ54.50 B 3,274.86%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ67.03 B 4,050.29%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.53 M-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ21.97 M-98.64%๐Ÿ‡บ๐Ÿ‡ธ USA